NVAX Stock Chart & Stats
$172.00
-$2.38(-1.78%)
At close: 4:00 PM EDT
$172.00
-$2.38(-1.78%)
Day’s Range― - ―
52-Week Range$115.00 - $240.00
Previous CloseN/A
Volume17.00
Average Volume (3M)574.00
Market Cap
$31.18B
Enterprise Value$1.13B
Total Cash (Recent Filing)$719.34M
Total Debt (Recent Filing)$295.60M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 05, 2026EPS Estimate
-4.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding164,945,720
10 Day Avg. Volume692
30 Day Avg. Volume574
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-8.52
Price to Sales (P/S)0.97
P/FCF Ratio-4.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$204.83Price Target Upside19.09% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-11.3
Revenue Forecast (FY)$6.44B
Bulls Say, Bears Say
Bulls Say
Platform TechnologyNovavax has a defined technology platform that can support multiple protein-based vaccine programs rather than relying on a single product concept. This provides a reusable foundation for future infectious-disease development and potential commercialization opportunities over the medium term.
Partner-Led Market AccessThe partnership model can broaden Novavax’s manufacturing and commercial reach while sharing development and distribution responsibilities. Contractual payments, reimbursements, royalties, or profit-sharing may also create multiple avenues for monetizing its vaccine technology beyond direct product sales.
Gross Margin And Profit CapabilityStrong gross margin and the ability to produce substantial operating and net profits in 2025 demonstrate that Novavax’s products can have attractive economics when revenue and procurement conditions are favorable. This offers a foundation for recovery if demand and delivery volumes stabilize.
Bears Say
Revenue ContractionThe sharp decline in trailing revenue indicates weakening commercial momentum and makes future operating leverage harder to achieve. Lower sales can reduce the scale benefits of the vaccine platform, pressure investment capacity, and leave results more dependent on the timing of individual contracts or deliveries.
Loss-Making Earnings ProfileThe swing from strong 2025 profitability back to operating and net losses shows that earnings are highly volatile rather than consistently self-sustaining. This instability complicates planning, limits internally funded growth, and increases the business risk attached to changes in vaccine demand and procurement timing.
Cash Burn And Weak SolvencyPersistent cash burn reduces Novavax’s ability to fund operations and development from internally generated resources. Combined with a continuing stockholders’ equity deficit, the pattern constrains financial flexibility and increases reliance on liabilities or external funding to sustain the business.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $115.00 and its highest was $240.00 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $31.18B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -$5.783 earnings per share for the quarter, beating the consensus estimate of -$6.868 by $1.084.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -4.19.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$5.783 in its last earnings report, beating expectations of -$6.868. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in MX:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$204.83 (19.09% Upside)
$204.83 (19.09% Upside)
Blogger Sentiment
Bullish
MX:NVAX Sentiment 93%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all MX:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$204.83
▲(19.09% Upside)